Preview Mode Links will not work in preview mode

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research


Dec 14, 2017

In this interview, Douglas L. Mann and Javed Butler discuss the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial and whether the risk of heart failure (HF) modulates the effectiveness of empagliflozin on HF hospitalization or cardiovascular death in patients with type 2 diabetes without HF.